Non small cell lung cancer treatment with vinorelbine monochemotherapy: a phase II study.
Non small cell lung cancer is one of the leading causes of death in the industrial countries and some 70% of patients have non surgically eradicable disease. Platinum based combined regimens can achieve 35-40% objective responses, but advanced age, low performance status and concurrent diseases can exclude up to 60% of patients from an adequate poliychemotherapy treatment.
Clerici
M
M
Ospadale San Carlo Borromeo, Divisione di Oncologia Medica, Milano, Italy.
Bretti
S
S
Celano
A
A
Panvini
D
D
Comandone
A
A
Casadio
C
C
Luporini
G
G
Bumma
C
C
D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
D014747:Vinblastine; D000077235:Vinorelbine